Mount Sinai Genetic Testing Laboratory Nearly Doubles Diseases Covered by Ashkenazi Jewish Carrier Screening Panel
With expanded screening test, 50 percent of Ashkenazi Jewish individuals are expected to be identified as carriers of at least one of the 38 diseases.
The Icahn School of Medicine at Mount Sinai today announced the launch of its Expanded Carrier Screening Panel for people of Ashkenazi Jewish descent. This test increases the number of diseases covered from 20 to 38, giving Ashkenazi Jewish individuals a 1 in 2 chance of being a carrier for at least one of the diseases. The 18 new diseases were added based on population screening studies performed by scientists at the Mount Sinai Genetic Testing Laboratory.
There are several genetic diseases that occur at increased frequencies in the Ashkenazi Jewish population. Because disease inheritance can be autosomal recessive or X-linked, many people are carriers without knowing it. Mount Sinai has been setting the bar for Ashkenazi Jewish carrier screening since 1997, when the Genetic Testing Laboratory initiated the triple-screen for Tay-Sachs disease, cystic fibrosis, and Gaucher disease. Additional disorders have been added steadily over the years as new genes were discovered.
Scientists at the Genetic Testing Laboratory recently conducted targeted mutation screening for disorders that were previously not included in standard Ashkenazi Jewish panels or were newly discovered in these patients. Based on screening of more than 2,000 Ashkenazi Jewish individuals, scientists identified 18 disorders as recurrent, with frequencies ranging from 1 in 36 to 1 in 373. For three of the disorders — Alport syndrome, multiple sulphatase deficiency, and dyskeratosis congenita — patients were seen by members of the Division of Medical Genetics at Mount Sinai, and the causative mutations were discovered through research studies and additional clinical testing.
“We have made consistent incremental progress with carrier screening for the Ashkenazi Jewish population since 1997, but this new screening panel represents the first major expansion of the test,” said Lisa Edelmann, PhD, Director of the Mount Sinai Genetic Testing Laboratory. “This is a giant step forward in helping people of Ashkenazi Jewish descent to comprehensively determine their risk for passing on one of these diseases.”
In addition to conducting the carrier screening panel at Mount Sinai, the Genetic Testing Laboratory will partner with additional commercial entities to make the testing more widely available.
“Feedback from clients, advocacy groups, and commercial testing organizations about this expanded panel has been very encouraging,” said Ruth Kornreich, PhD, Director of Molecular Genetics at the Mount Sinai Genetic Testing Laboratory. “The positive responses have been due in part to our reputation in delivering comprehensive carrier screening to the Ashkenazi Jewish community.”
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community‐based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12‐minority‐owned free‐standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.